RxDoctor Payments Data

Chetan Sharma, MD

Family Medicine · Locust Grove, GANPI 1871763011

Payments from drug & device makers

$2,373in general payments, 2019–2025

Across 117 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$398
  • AstraZeneca$330
  • Lilly USA, LLC$187
  • Amarin Pharma, Inc.$141
  • Astellas Pharma US Inc$138
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,27396%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,373 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$32,670
Medicare patients
80
Services billed
1,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide20$32,678
JanuviaSitagliptin Phosphate23$31,428
FarxigaDapagliflozin Propanediol19$28,465
JardianceEmpagliflozin19$26,407
TrulicityDulaglutide13$23,167
EliquisApixaban12$15,267
Albuterol Sulfate HfaAlbuterol Sulfate26$1,242
Rosuvastatin Calcium78$745
Simvastatin73$615
Atorvastatin Calcium101$587
Losartan Potassium86$578
Potassium Chloride44$570
Amlodipine Besylate128$502
Lisinopril82$491
Levothyroxine Sodium61$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$131$32,67820 claims
MerckJanuvia$28$31,42823 claims
AstraZenecaFarxiga$330$28,46519 claims
Boehringer IngelheimJardiance$46$26,40719 claims
Lilly USA, LLCTrulicity$187$23,16713 claims
PfizerEliquis$128$15,26712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Locust Grove

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →